Skip to content

Is This Biotech With An Innovative Drug Pipeline A Buy?

The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near term, CLICK HERE.